KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $201.2 million.

  • Sarepta Therapeutics' Net Income towards Common Stockholders rose 285875.0% to $201.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $360.0 million, marking a year-over-year increase of 19291.94%. This contributed to the annual value of $235.0 million for FY2024, which is 14382.98% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Net Income towards Common Stockholders of $201.2 million as of Q2 2025, which was up 285875.0% from $158.8 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Net Income towards Common Stockholders ranged from a high of $201.2 million in Q2 2025 and a low of -$516.8 million during Q1 2023
  • For the 5-year period, Sarepta Therapeutics' Net Income towards Common Stockholders averaged around -$71.9 million, with its median value being -$48.1 million (2021).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 85615.14% in 2021, then soared by 285875.0% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Net Income towards Common Stockholders stood at -$122.0 million in 2021, then rose by 9.94% to -$109.9 million in 2022, then soared by 141.44% to $45.5 million in 2023, then soared by 248.8% to $158.8 million in 2024, then rose by 26.7% to $201.2 million in 2025.
  • Its last three reported values are $201.2 million in Q2 2025, $158.8 million for Q4 2024, and $34.0 million during Q3 2024.